Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cohort Analysis
100%
Maturity Onset Diabetes of the Young
75%
Patient with Type 2 Diabetes
68%
Diabetes
64%
COVID-19
49%
Nonalcoholic Fatty Liver
39%
Impaired Glucose Tolerance
29%
Randomized Controlled Trial
29%
Hemoglobin A1c
28%
Glycemic
26%
Hazard Ratio
24%
Fibrosis
24%
Propensity Score Matching
21%
Heart Surgery
19%
Titrimetry
19%
Ultrafiltration
19%
Liver Fibrosis
19%
Patient with Diabetes
19%
Odds Ratio
19%
Diabetes Mellitus
17%
Chronic Kidney Disease
16%
Glycated Hemoglobin
16%
Coronary Artery Calcium
14%
Homeostatic Model Assessment
14%
Insulin Dependent Diabetes Mellitus
14%
Cardiovascular Disease
13%
Insulin Resistance
13%
Dipeptidyl Peptidase-4 Inhibitor
12%
Physical Activity
11%
Fatty Liver
11%
Health Care Cost
11%
Glycemic Control
11%
Mass Screening
10%
Transferrin Receptor
9%
Adrenal Cortex Carcinoma
9%
Acromegaly
9%
Vertebra
9%
Continuous Glucose Monitor
9%
Lipotoxicity
9%
Resistance Index
9%
Treatment Group
9%
Transcatheter Arterial Chemoembolization
9%
Hepatocellular Carcinoma
9%
Coronary Computed Tomography Angiography
9%
Endocrinologist
9%
Hyperglycemia
9%
Gluconeogenesis
9%
Sodium Glucose Cotransporter 2
9%
Proton-Pump Inhibitor
9%
Computed Tomography Angiography
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
42%
Cohort Study
41%
Nonalcoholic Fatty Liver
39%
Maturity Onset Diabetes of the Young
39%
Chronic Kidney Failure
21%
Insulin Resistance
19%
Fibrosis
19%
Dipeptidyl Peptidase IV Inhibitor
19%
Liver Fibrosis
18%
Hypoglycemia
12%
Fatty Liver
12%
Diabetes Mellitus
11%
Diseases
10%
Acromegaly
9%
Adrenal Cortex Carcinoma
9%
Coronavirinae
9%
Lipotoxicity
9%
Proton Pump Inhibitor
9%
Clusterin
9%
sodium glucose cotransporter-2 inhibitors
9%
G Protein Coupled Receptor 120
9%
Sodium Glucose Cotransporter 2
9%
Glucagon Like Peptide Receptor Agonist
9%
Thyroid Cancer
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Microbiome
9%
All Cause Mortality
9%
Cancer Mortality
9%
Liver Disease
9%
Low Density Lipoprotein Cholesterol
9%
End Stage Renal Disease
9%
Hemoglobin A1c
7%
Sodium Glucose Cotransporter
6%
SARS Coronavirus
6%
Placebo
5%
Biochemistry, Genetics and Molecular Biology
Upregulation
21%
Palmitic Acid
20%
Programmed Cell Death
19%
Autophagy
19%
Glycemic Control
19%
Glycated Hemoglobin
13%
Triglyceride
12%
Kidney Function
9%
Transferrin Receptor
9%
Lipid Profile
9%
HDL-Cholesterol
9%
Aldosterone
9%
Randomized Controlled Trial
9%
Lipotoxicity
9%
Proteomics
9%
Glucose Level
9%
Mechanistic Target of Rapamycin
9%
Clusterin
9%
Mass Spectrometry
9%
Docosahexaenoic Acid
9%
G Protein Coupled Receptor
9%
Cancer Mortality
9%
All Cause Mortality
9%
Cohort Study
9%
Psychological Well-Being
9%
Behavioral Change
9%
Dynamics
9%
Clinical Decision Making
9%
Translating (Language)
9%
Self Concept
9%
Lipid Metabolism
7%
Triacylglycerol Level
6%
Total Cholesterol Level
6%
Renin
6%
Light Chain
6%
Beta Oxidation
5%